Quintet Private Bank Europe S.A. Has $9.12 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Quintet Private Bank Europe S.A. boosted its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.9% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 359,915 shares of the biopharmaceutical company's stock after purchasing an additional 23,332 shares during the quarter. Quintet Private Bank Europe S.A.'s holdings in Pfizer were worth $9,120,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of PFE. NorthCrest Asset Manangement LLC increased its holdings in shares of Pfizer by 16.5% in the 1st quarter. NorthCrest Asset Manangement LLC now owns 45,391 shares of the biopharmaceutical company's stock valued at $1,150,000 after acquiring an additional 6,440 shares during the last quarter. Willis Investment Counsel increased its holdings in shares of Pfizer by 7.3% in the 1st quarter. Willis Investment Counsel now owns 1,522,428 shares of the biopharmaceutical company's stock valued at $38,578,000 after acquiring an additional 103,590 shares during the last quarter. Thomasville National Bank increased its holdings in shares of Pfizer by 5.4% in the 1st quarter. Thomasville National Bank now owns 85,372 shares of the biopharmaceutical company's stock valued at $2,163,000 after acquiring an additional 4,358 shares during the last quarter. Rockland Trust Co. increased its holdings in shares of Pfizer by 5.8% in the 1st quarter. Rockland Trust Co. now owns 454,543 shares of the biopharmaceutical company's stock valued at $11,518,000 after acquiring an additional 25,029 shares during the last quarter. Finally, Union Bancaire Privee UBP SA increased its holdings in shares of Pfizer by 12.1% in the 1st quarter. Union Bancaire Privee UBP SA now owns 185,982 shares of the biopharmaceutical company's stock valued at $4,430,000 after acquiring an additional 20,053 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on PFE shares. The Goldman Sachs Group reiterated a "neutral" rating and issued a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. UBS Group boosted their price target on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Stock Performance

PFE traded down $0.33 during trading on Friday, reaching $24.51. 46,354,360 shares of the company were exchanged, compared to its average volume of 41,162,088. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The firm has a 50 day moving average of $23.01 and a 200 day moving average of $24.97. The stock has a market cap of $139.35 billion, a P/E ratio of 17.38, a PEG ratio of 0.64 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the previous year, the firm posted $0.82 EPS. The firm's quarterly revenue was down 7.8% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.02%. Pfizer's dividend payout ratio (DPR) is presently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.